When a Food and Drug Administration advisory panel meets Monday to size up an Eli Lilly experimental Alzheimer’s drug, questions about safety, selection of patients for treatment, and dosing will be at the fore, documents released Thursday show.
More Stories
The Fed decision’s lone dissenter worries the bigger rate cut sends a ‘premature victory’ message to markets
Michelle Bowman was the first Federal Reserve governor to dissent from an interest-rate decision since 2005.
Tech giants desperate to power AI data centers are turning to nuclear disaster sites — despite the risks
The tech industry’s need for more power for data centers running artificial intelligence is now so desperate that companies are...
Jamie Dimon: Only 5% of everyday Americans probably know about the Fed’s historic interest-rate cut
JPMorgan Chase CEO Jamie Dimon suggests the half-point interest-rate cut is “a minor thing” that Wall Street — not Main...
Uranium ETFs rally amid plans to revive nuclear reactor in Microsoft agreement
Constellation Energy said Friday it plans to restart a nuclear reactor at Three Mile Island.
The Fed rate cut scared me. Where should I invest my $127,000 in savings now?
This reader wonders whether CD rates, high-yield savings accounts and bond ladders are still smart moves, even if interest rates...
The fan who caught Shohei Ohtani’s 50th home-run ball could make $500,000
Aaron Judge’s 62nd home-run ball in 2022 sold for $1.5 million at auction